How Syncona built a $1Billion Dollar NAV Portfolio - Roel Bulthuis episode artwork

EPISODE · Dec 2, 2025 · 45 MIN

How Syncona built a $1Billion Dollar NAV Portfolio - Roel Bulthuis

from Leading Beyond The Lab

🤔 What does it really take to build a biotech that survives the clinical gauntlet and scales into a global business?🎬 This week on Leading Beyond The Lab, Lawrence Rose sat down with Roel Bulthuis, Managing Partner and Head of Investments at Syncona Limited. Roel has spent his career building, funding and scaling European biotech companies end-to-end, supporting high-performing teams from inception through clinical development, commercial launch and manufacturing scale-up. Along the way he references outcomes from portfolio companies such as Autolus Therapeutics and Beacon Therapeutics, showing how patient capital and conviction-led strategy compound over time.⭐️ Syncona has an impressive portfolio including,Autolus Therapeutics, Beacon Therapeutics, Spur Therapeutics, iOnctura, Quell Therapeutics, ANAVEON AG, MOSAIC THERAPEUTIC SERVICES, Resolution Therapeutics, Purespring Therapeutics, Forcefield Therapeutics, OMass Therapeutics, Kesmalea Therapeutics, Yellowstone Biosciences, Slingshot Therapeutics.🚀 In this episode, Roel dives into:- What defines a Syncona company and its unique model- Key lessons learned from both successes and setbacks- How to manage investor involvement without stifling progress- The challenges of leadership transitions within portfolio companies- Syncona’s strategic commitment to the European market- What drives Roel personally and what he enjoys most about his roleCheck out this episode if you want grounded insight into biotech venture building, long-term capital strategy and how scientific founders scale from the lab to patient impact. 🤝Follow ARTO!LinkedIn: https://www.linkedin.com/company/artotalentSpotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qrTikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Website: https://arto-talent.comYoutube: https://www.youtube.com/@life_sciences Lawrence RoseCo-Founder + Talent Solutions Director at @ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Role BulthuisManaging Partner @SynconaLinkedIn: https://www.linkedin.com/in/roel-bulthuis-aa414a/Timestamps:01:10 What makes up a Syncona company?11:25 What were the main lessons learnt from previous failures/successes?15:06 Managing investor involvement & preventing counter productivity.22:14 The issues with exchanging leadership.31:07 Commitment to the European Market.42:20 What Roel enjoys about his job. Hosted on Acast. See acast.com/privacy for more information.

Episode metadata supplied by the publisher feed · Published Dec 2, 2025

Embed this episode

NOW PLAYING

How Syncona built a $1Billion Dollar NAV Portfolio - Roel Bulthuis

0:00 45:29

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Leading Beyond The Lab?

This episode is 45 minutes long.

When was this Leading Beyond The Lab episode published?

This episode was published on December 2, 2025.

Can I download this Leading Beyond The Lab episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!